Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 26, 2025
BioCardia Reports 2024 Business Highlights and Financial Results
GlobeNewswire
·
March 26, 2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended …
Tilray Successfully Prevails with Dismissal of HEXO Shareholder Lawsuit
GlobeNewswire
·
March 26, 2025
NEW YORK and LEAMINGTON, Ontario, March 26, 2025 (GLOBE NEWSWIRE) -- Tilray Brands Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), and its subsidiary HEXO Corporation (“HEXO”), announced the successful dismissal of the Clement Italume vs. Robinhood Markets Inc …
Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
·
March 26, 2025
Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care …
Prime Biome Reviews (URGENT ALERT) Users Expose Facts About The Digestive Side Effects & Benefits You Haven’t Heard Yet
GlobeNewswire
·
March 26, 2025
Seattle, March 26, 2025 (GLOBE NEWSWIRE) -- Prime Biome Gut health and skin care have always been treated as separate issues, with people relying on skincare products for clearer skin and digestive aids for bloating or discomfort. But what if the secret …
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
GlobeNewswire
·
March 26, 2025
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved …
Jobma Recognized as Momentum Leader and Grid Leader in G2’s Spring 2025 Report
EIN Presswire
·
March 26, 2025
Jobma secures Momentum Leader and Grid Leader awards in G2's Spring 2025 Report, showcasing its impact in transforming modern hiring processes. MINNETONKA, MN, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Jobma, a leading AI video interviewing …
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
GlobeNewswire
·
March 26, 2025
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy regimens, and presented with multiple …
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
GlobeNewswire
·
March 26, 2025
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team …
Dyadic Reports 2024 Year-End Financial Results and Business Updates
GlobeNewswire
·
March 26, 2025
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture …
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewswire
·
March 26, 2025
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less …
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
March 26, 2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a …
CRISPR Therapeutics Announces Transition of Chief Operating Officer
GlobeNewswire
·
March 26, 2025
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, …
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
GlobeNewswire
·
March 26, 2025
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 …
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 26, 2025
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial …
Inventiva reports its 2024 full year results and provides a business update
GlobeNewswire
·
March 26, 2025
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 million Last patient screened in the …
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
GlobeNewswire
·
March 26, 2025
Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée d’un produit brut de 116 millions d’euros dans le cadre de la première tranche du Financement Structuré …
Heartflow Closes $98 Million Convertible Notes Financing
GlobeNewswire
·
March 26, 2025
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced additional investments in the company of approximately $98 million through the sale and issuance of …
Mitolyn Reviews (URGENT CLINICAL REPORT) Real Users Expose the Truth About Its Metabolism-Boosting Claims
GlobeNewswire
·
March 26, 2025
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Mitolyn When it comes to weight loss supplements, consumer experiences and real-world results matter more than marketing hype. With Mitolyn gaining rapid attention, people are asking the same questions: Does …
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
GlobeNewswire
·
March 26, 2025
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that …
Protecting 2SLGBTQ+ Seniors in Ontario: Rainbow Faith and Freedom Launches Crucial Initiative
GlobeNewswire
·
March 26, 2025
TORONTO, March 26, 2025 (GLOBE NEWSWIRE) -- Rainbow Faith and Freedom (RFF) has launched an important initiative to address the challenges faced by 2SLGBTQ+ seniors living in senior care facilities across Ontario. This project seeks to ensure that queer …